Peijia Medical (9996.HK)

Executive Summary

Peijia Medical is a leading Chinese medical device company focused on transcatheter aortic valve replacement (TAVR) and neurovascular interventional devices. Founded in 2012 and listed on the Hong Kong Stock Exchange (9996.HK), the company has developed a portfolio of innovative products including the TaurusOne and TaurusElite TAVR systems, which are designed for minimally invasive treatment of aortic stenosis. Peijia also addresses the growing demand for neurovascular interventions, particularly for stroke treatment with devices like the Nyxoft embolic coil. The company's strategic 'heart-brain co-treatment' approach positions it to leverage synergies across these two high-growth segments within China's expanding medical device market. Peijia is well-positioned to capitalize on favorable demographic trends, including China's aging population and increasing prevalence of valvular heart disease and neurovascular conditions. The company benefits from a strong distribution network, regulatory support for domestic innovation, and a robust pipeline of next-generation products. Revenue growth is expected to accelerate due to expanding TAVR adoption, driven by favorable clinical data and upgraded product features. While competition from global players (e.g., Edwards Lifesciences) and domestic rivals remains a risk, Peijia's differentiated technology and cost advantages provide a competitive edge. The company's focus on both structural heart and neurovascular markets offers diversification and long-term growth potential.

Upcoming Catalysts (preview)

• Q3 2026Approval of TaurusElite for bicuspid aortic stenosis indication in China70% success
• Q1 2027Positive clinical data readout for Nyxoft embolic coil in acute ischemic stroke60% success
• Q2 2026Q2 2026 earnings beat driven by stronger-than-expected TAVR volume growth75% success